Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Wendy Rabbenou

Gastroenterology New York, NY Medical Doctor

NPI 1225442379 CMS profile 8794062

111 E. 210 Street, New York, NY 10467

Open in the dashboard

General payments

$84,265

248 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Rabbenou of New York, NY is reported in the CMS Open Payments database as having received $84,265 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $947 52
2024 General $1,533 101
2023 General $800 45
2022 General $674 30
2021 General $39,453 18
2020 General $40,858 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Rabbenou
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Wendy Rabbenou were reported at $947. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Wendy Rabbenou Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $40,858 $224 $74–$624 $114
2021 $39,453 $352 $106–$1,054 $132
2022 $674 $448 $129–$1,270 $149
2023 $800 $533 $150–$1,390 $160
2024 $1,533 $605 $160–$1,606 $164
2025 $947 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Pfizer Inc. $80,140 10 payments
  2. AbbVie, Inc. $1,235 73 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $694 54 payments
  4. Janssen Biotech, Inc. $462 29 payments
  5. Celgene Corporation $376 28 payments
  6. E.R. Squibb & Sons, L.L.C. $271 3 payments
  7. QOL Medical, LLC $244 13 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $179 10 payments
  9. Madrigal Pharmaceuticals $135 1 payment
  10. CONMED Corporation $98 1 payment
  11. Other $431 26 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $80,000 2 payments
  2. Food and Beverage $4,265 246 payments
Products named General payments · program years 2020–2025
  1. RINVOQ $596 42 payments
  2. XIFAXAN $464 35 payments
  3. ZEPOSIA $417 29 payments
  4. SKYRIZI Immunology $373 25 payments
  5. TREMFYA $353 22 payments
  6. STELARA $274 14 payments
  7. SKYRIZI Immunology $259 21 payments
  8. TRULANCE $196 17 payments
  9. ENTYVIO $179 10 payments
  10. Sucraid $154 7 payments
  11. Other $1,515 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

486

Median for Gastroenterology: 569

Drug cost

$1,919,552

Median for Gastroenterology: $104,976

Branded share of claims

29%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 73 $1,894,498
Mesalamine Generic 27 $12,771
Colestipol Hcl Generic 11 $3,216
Pantoprazole Sodium Generic 138 $2,706
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 13 $1,733
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 25 $1,694
Omeprazole Generic 77 $1,240
Loperamide Loperamide Hcl Brand 18 $402
Dicyclomine Hcl Generic 24 $401
Esomeprazole Magnesium Generic 12 $299

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$43,398

Medicare's payments for the services billed

Medicare patients

189

Average age 73

Services billed

409

126 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 58%
Diabetes 36%
Chronic kidney disease 29%
Depression 29%
Ischemic heart disease 27%
Osteoporosis 26%
Cancer 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $268
$268 — —
SKYRIZI
  • AbbVie, Inc. $266
$266 — —
STELARA
  • Janssen Biotech, Inc. $127
$127 73 —
RINVOQ
  • AbbVie, Inc. $116
$116 — —
Sucraid
  • QOL Medical, LLC $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record